References

^1. Beck CK, Cody M, Zhang M. A multidisciplinary approach to managing Alzheimer's disease. Pharmacotherapy 1998;18(2 Pt 2):33S-42S.

² Alzheimer, A: A new disease of the cortex (Ger), Allg Z Psychiatr 64: 146-148, 1907.

³ Evans DA, Funkenstein HH, Albert MS, et al. Prevalence of Alzheimer's disease in a community population of older persons; higher than previously reported. JAMA1989;262:2551-2556.

⁴ Gurland BJ, Wilder DE, Lantigua R, et al. Rates of dementia in three ethnoracial groups. Int J Geriatric Psychiatry 1999;14(6):481-93.

⁵ Evans RM, Emsley CL, Gao S, et al. Serum cholesterol, APOE genotype, and the risk of Alzheimer's disease: a population-based study of African Americans. Neurology 2000; 54(1):240-2.

⁶ Stern Y,Tang MX, Albert MS, et al. Predicting time to nursing home care and death in individuals with Alzheimer disease. JAMA 1997;277(10):806-12.

⁷ Leon J, Cheng CK, Neumann PJ. Alzheimer's disease: cost and potential savings. Health Affairs 1998;17(6):206-216.

⁸ Stommel M, Collins CE, Given BA. The costs of family contributions to the care of persons with dementia. Gerontologist 1997;34:199-205.

⁹ Schulz R, Beach SR. Caregiving as a risk factor for mortality :the caregiver health effects study. JAMA 1999;282:2215-2219.

¹⁰ Knopman D, Schneider L, Davis K et al. Long-term tacrine treatment: effects on nursing home placement and mortality. Neurology 1996;47:166-77.

¹¹ Small G, Donohue JA, Brooks RL. An economic evaluation of donepezil in the treatment of Alzheimer's disease. Clin Therapeutics 1998;20(4):838-850.